CRVS insider trading
NasdaqGM HealthcareCorvus Pharmaceuticals, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell atopic dermatitis, asthma, psoriasis, and fibrotic diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.
Company website: www.corvuspharma.com
CRVS insider activity at a glance
FilingIQ has scored 233 insider transactions for CRVS since Mar 22, 2016. The most recent filing in our index is dated Apr 23, 2026.
Across the full history, 109 open-market purchases
and 11 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on CRVS insider trades is 55.4/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest CRVS Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for CRVS?
- FilingIQ tracks 233 Form 4 insider transactions for CRVS (Corvus Pharmaceuticals, Inc.), covering filings from Mar 22, 2016 onwards. 1 of those were filed in the last 90 days.
- Are CRVS insiders net buyers or net sellers?
- Across the full Form 4 history for CRVS, 109 transactions (47%) were open-market purchases and 11 (5%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does CRVS insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is CRVS in?
- Corvus Pharmaceuticals, Inc. (CRVS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.49B.
Methodology & sources
Every CRVS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.